HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Energy Drink Plans Earn Durbin’s Stamp; Firms Meet With Agency

This article was originally published in The Tan Sheet

Executive Summary

Senate critics say FDA “is moving forward in a number of areas to protect vulnerable populations against high levels of caffeine in energy drinks.” Monster Energy and Rockstar representatives tell FDA their products are safe. Rep. Markey asks FTC to scrutinize advertising for the products.

You may also be interested in...



Energy Drink Concerns Could Tilt Congress Toward DSHEA Changes

Supplement industry stakeholders see deaths reported in energy drinks AERs as a potential rallying point for Capitol Hill to consider tightening oversight of the industry. Senators Durbin and Blumenthal question FDA’s investigation of the deaths and ask for more action by the agency.

Senators Call For FDA Briefing On Energy Drink Review

Following media stories on deaths in AERs about energy drinks, Sens. Durbin and Blumenthal ask FDA to brief them on the agency’s investigation into the products, to assess health risks associated with caffeine consumption by adolescents, and to finalize guidance distinguishing liquid supplements from beverages.

Four Alcoholic Energy Drink Warnings Should Shake Up The Market – FDA

FDA expects warning letters to four firms marketing alcoholic energy drinks to prompt a nationwide halt to sales of the products without further regulatory action.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel